Merus (MRUS)
(Delayed Data from NSDQ)
$44.52 USD
-0.60 (-1.33%)
Updated May 10, 2024 04:00 PM ET
After-Market: $44.47 -0.05 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MRUS 44.52 -0.60(-1.33%)
Will MRUS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRUS
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Other News for MRUS
Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)
Merus GAAP EPS of -$0.59 beats by $0.20, revenue of $7.89M misses by $0.45M
Interesting MRUS Put And Call Options For December 2025
Buy Rating Affirmed on Merus’s Clinical and Financial Prospects
Buy Rating Affirmed for Merus on Promising HNSCC Clinical Data and Competitive Outlook